SCHEMBL2851878

SCHEMBL2851878

CCCc1cc(C(=O)CC)ccc1-c1cc(OCc2ccc(COC(=O)c3ccccc3)c(COC(=O)c3ccccc3)c2)ccc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
MAPT P10636 4/20 0.44
ALDH1A1 P00352 2/20 0.44
HTT P42858 2/20 0.44
GAA P10253 2/20 0.44
VDR P11473 1/20 0.42
NPC1 O15118 4/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
PPARG P37231 1/20 0.37
MRGPRX4 Q96LA9 2/20 0.37
HSP90AA1 P07900 1/20 0.37
FFAR1 O14842 5/20 0.37
FFAR4 Q5NUL3 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
HPGD P15428 1/20 0.36
PPARD Q03181 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858864 0.93 VDR (0.49) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL2852532 0.87 SMN1; SMN2 (0.48) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL2863416 0.85 VDR (0.58) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL6566321 0.83 MRGPRX4 (0.48) RAB9ASMN1; SMN2ALDH1A1HTTMRGPRX4
SCHEMBL6888088 0.82 PPARG (0.46) SMN1; SMN2MAPTALDH1A1HTTKMT2A
SCHEMBL6886884 0.81 MRGPRX4 (0.43) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL2855100 0.80 SMN1; SMN2 (0.44) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL6565076 0.80 MRGPRX4 (0.47) RAB9ASMN1; SMN2ALDH1A1HTTNPC1
SCHEMBL2863419 0.79 RAB9A (0.42) RAB9ASMN1; SMN2MAPTALDH1A1HTT
SCHEMBL6562842 0.78 MRGPRX4 (0.47) RAB9ASMN1; SMN2KMT2AMEN1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456160-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2010-01-20 EP disclosed
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
EP-1456160-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2004-09-15 EP disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed
WO-2003050067-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR RAB9A 3535/4885SMN1; SMN2 4849/4885MAPT 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.